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Objective: Accurate pretreatment staging in non–small cell lung cancer remains tan-
tamount in formulating an appropriate treatment plan. The maximum standardized
uptake value obtained with integrated fluorodeoxyglucose–positron emission
tomography/computed tomography has been proposed to be a predictor of malig-
nancy in mediastinal lymph nodes. A recent study has also suggested that accuracy
of integrated fluorodeoxyglucose–positron emission tomography/computed tomogra-
phy might be improved by increasing the maximum standardized uptake value used
for calling a lymph node positive from 2.5 to 5.3. We tested the hypotheses that the
maximum standardized uptake value is a predictor of individual lymph node metas-
tasis in non–small cell lung cancer and that pathologic staging with mediastinoscopy
might not be necessary in patients with a maximum standardized uptake value of less
than 5.3 in their mediastinal lymph nodes.
Methods: This is a retrospective review of 765 lymph nodes sampled from 110 pa-
tients in a single institution with biopsy-proved non–small cell lung cancer. All
patients underwent integrated fluorodeoxyglucose–positron emission tomography/
computed tomography before biopsy or resection of their mediastinal lymph nodes.
Surgical staging was the reference standard. All N2 lymph nodes were individually
assessed according to station. Data were analyzed by using the Pearson c2 test.
Results: Twenty-one (19%) of 110 patients had N2 disease, and a total of 765 N2 lymph
nodes were pathologically examined. The mean and median maximum standardized
uptake values for N2 nodes with metastatic disease were 9.2 (95% confidence interval,
7.0–11.4) and 7.2 (range, 2.2–25.8), respectively. For benign N2 nodes, the mean and
median maximum standardized uptake values were 1.5 (95% confidence interval, 1.4–
1.6) and 1.0 (range, 1.0–9.6), respectively (P, .05). When integrated fluorodeoxyglu-
cose–positron emission tomographic/computed tomographic scans were reinterpreted
by using a maximum standardized uptake value of 5.3 as a cutoff for malignancy, sen-
sitivity decreased from 93% to 81% (P5 .15), specificity increased from 86% to 98%
(P, .01), positive predictive value increased from 22% to 64% (P, .01), negative pre-
dictive value was unchanged at 99%, and overall accuracy of integrated positron emis-
sion tomography/computed tomography increased from 87% to 97% (P, .01).
Conclusions: The maximum standardized uptake value is a predictor of individual
lymph node metastasis in non–small cell lung cancer. Accuracy of integrated positron
emission tomography/computed tomography is significantly improved by using
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TSa maximum standardized uptake value of 5.3 to assign malig-
nancy, thereby dramatically decreasing the number of false-
positive results. More importantly, these results suggest
that some patients with non–small cell lung cancer with
a maximum standardized uptake value less than 5.3 in their
N2 lymph nodes might be able to forego mediastinoscopy
and proceed directly to thoracotomy. This represents a signif-
icant change in the current management of standardized
uptake value–positive mediastinal lymph nodes in non–small
cell lung cancer.
N
on–small cell lung cancer (NSCLC) remains the
leading cause of cancer death in America.1
Because treatment of NSCLC is allocated by stage,
accurate pretreatment staging is an absolute necessity.
Although computed tomography (CT) or standard positron
emission tomography (PET) have historically been the
benchmarks for noninvasive staging, multiple studies have
now validated integrated PET/CT as the new gold standard
in noninvasive pretreatment staging.2-4
The major benefit of integrated PET/CT is derived from its
ability to combine form with function. Malignant cells with
a high metabolic activity have a greater uptake of fluorodeox-
yglucose (FDG) and can be anatomically correlated and dis-
tinguished from the surrounding tissues. However, the major
pitfall of integrated PET/CT lies in its high false-positive rate
because infections and other inflammatory conditions can
frequently mimic malignancy.5,6 Thus pathologic confirma-
tion of a positive PET/CT result by means of mediastino-
scopy or fine-needle aspiration (FNA) is considered
mandatory.7,8
What remains unclear is the notion of what constitutes
a positive finding on integrated PET/CT because it is not in-
frequent to find mediastinal regions described as having
‘‘low’’ or ‘‘mild’’ uptake. This indeterminate finding on
PET/CT leaves most practitioners in a quandary as to whether
pathologic confirmation is needed to verify N2/N3 disease
because this might expose many patients to unnecessary in-
vasive staging procedures, such as mediastinoscopy, which
carry multiple risks, including hemorrhage or vocal cord in-
jury.9 Recent evidence has renewed interest in the utility of
standardized uptake values in predicting malignancy.10,11
Specifically, the maximum standardized uptake value (max-
SUV) has been shown to be an independent predictor of ma-
lignancy and of lymph node metastasis. Suggestion has also
been made that a defined cutoff point of 5.3 for lymph node
metastases provides maximum accuracy with integrated
PET/CT.12
We elected to test the hypotheses that the maxSUV is
a predictor of individual lymph node metastasis in NSCLC
and that pathologic staging with mediastinoscopy might not
be necessary in patients with a maxSUV of less than 5.3 in
their mediastinal lymph nodes.616 The Journal of Thoracic and Cardiovascular Surgery c MaAbbreviations and Acronyms
CT 5 computed tomography
FDG 5 fluorodeoxyglucose
FNA 5 fine-needle aspiration
maxSUV 5 maximum standardized uptake value
NSCLC 5 non–small cell lung cancer
PET 5 positron emission tomography
Materials and Methods
Patient Selection
A retrospective review was performed on all N2 lymph nodes sam-
pled from patients by using cervical mediastinoscopy, anterior
mediastinotomy, and/or thoracotomy between December 2003 and
June 2006 on the thoracic surgery service at the University of Cal-
ifornia at Davis Cancer Center. Only N2 lymph nodes from patients
with new diagnoses of biopsy-proved NSCLC and presurgical stag-
ing–integrated PET/CT scans were included. The integrated PET/
CT scans were then compared with the reference standard of patho-
logic results to determine sensitivity, specificity, positive and nega-
tive predictive values, and accuracy. The Institutional Review Board
at the University of California at Davis Medical Center approved
this study.
Integrated PET/CT Imaging
All integrated PET/CT studies were performed after patient fasting
for a minimum of 4 hours. PET/CT images were obtained with an
integrated PET/CT scanner (Discovery LS from GE Medical Sys-
tems, Waukesha, Wis, or ECAT Reveal XVI from CTI, Knoxville,
Tenn) at 2 PET imaging centers. Whole-body scans were obtained
30 to 60 minutes after intravenous injection of 10 to 20 mCi of
[18F] fluoro-2-deoxy-D-glucose. For PET/CT imaging, simulta-
neously acquired CT data were used for attenuation correction.
All studies were read by dedicated nuclear medicine physicians
with a specialty in interpreting PET scan images. Clinical histories
and pertinent CT scans were available for review. Mediastinal
lymph nodes were individually assessed and assigned maxSUVs
by using software contained within the PET/CT scanner and the fol-
lowing formula: MaxSUV5CðmCi=mLÞ=IDðmCiÞwðkgÞ, with C
equal to the activity at a pixel within a region of interest and ID equal
to the injected dose per kilogram of patient body weight (w).13
Mediastinal Lymph Node Staging
Extended mediastinal lymph node staging was completed in all pa-
tients by means of cervical mediastinoscopy, anterior mediastinot-
omy, or thoracotomy. In patients with normal mediastinoscopic
results, thoracotomy followed typically within 14 days. The results
of PET and CT scanning were available to the surgeon at the time of
resection. All visible and technically feasible lymph nodes were re-
moved and were annotated according to the revised International
Staging System.14,15 Pathologic reports were reviewed to determine
whether any mediastinal lymph nodes contained cancer. Only N2
lymph nodes that would have been accessible by means of mediasti-
noscopy (stations 2, 4, and 7), anterior mediastinotomy (stations 5
and 6), right thoracotomy (stations 2, 4, 7, 8, and 9), or left thoracot-
omy (4, 5, 6, 7, and 9) were considered in this study.rch 2008
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Pathologic findings served as the gold standard. Each lymph node
was individually assessed both clinically and pathologically. Thus
it was possible for an individual patient to have, for example, 2
true-positive, 4 true-negative, and 2 false-positive lymph nodes.
Comparisons between groups were made with the c2 test or the
Mann-Whitney test. Receiver operator characteristic curves were
produced by using the SPSS Version 13.0 for Windows (SPSS,
Inc, Chicago, Ill).
Results
Between December 2003 and June 2006 at the University of
California at Davis Cancer Center, a total of 142 patients un-
derwent surgical mediastinal lymph node biopsy, with an av-
erage of 4 mediastinal lymph node stations sampled. Of the
32 patients excluded from this study, 19 either did not have
an integrated PET/CT scan or did not have maxSUV values
assigned, and 13 did not have a new diagnosis of NSCLC.
A total of 1311 lymph nodes were resected from the re-
maining 110 patients, of which 51 (46.4%) of 110 were
men. Additional patient characteristics are shown in Table
1. There were 546 N1 lymph nodes and 765 N2 lymph nodes.
There was pathologic evidence of metastasis in 31 (4.1%) of
TABLE 1. Patient characteristics
Characteristic
Integrated PET/CT study
population (n 5 110)
Age (y)
Mean 65
Range 32–86
Male sex (%) 51 (46.4)
N2/N3 mediastinal disease (%) 21 (19.1)
Primary tumor location (%)
RUL 37 (33.6)
RML 2 (1.8)
RLL 25 (22.7)
LUL 35 (31.8)
LLL 11 (10)
PET, Positron emission tomography; CT, computed tomography; RUL, right
upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper
lobe; LLL, left lower lobe.The Journal of Thor765 N2 lymph nodes in 21 (19.1%) of 110 patients. Table 2
shows the distribution and median maxSUV of each medias-
tinal lymph node station. Station 4 was the most common
location for metastatic disease. The mean and median
maxSUVs for N2 nodes with metastatic disease were 9.2
(95% confidence interval, 7.0–11.4) and 7.2 (range, 2.2–
25.8), respectively. For benign N2 nodes, the mean and me-
dian maxSUVs were 1.5 (95% confidence interval, 1.4–1.6)
and 1.0 (range, 1.0–9.6), respectively (P , .05).
The optimal maxSUV cutoff for mediastinal lymph nodes
was 5.3 by means of receiver operator characteristic analysis,
as shown in Figure 1. When a maxSUV of 5.3 instead of 2.5
was used to assign malignancy by means of integrated PET/
CT scanning, there were significant increases in overall
Figure 1. Receiver operating characteristic curve for N2 lymph
nodes. Dotted lines indicate 95% confidence intervals. Optimal
maximum standardized uptake value cutoff was 5.3 (P < .001).TABLE 2. Distribution and median maxSUV of N2 lymph nodes
Pathologically positive nodes Pathologically negative nodes
Lymph node station N maxSUV range (median) N maxSUV range (median) P value*
2 5 2.0–20.9 (7.2) 62 1.0–2.5 (1) ,.001
4 12 2.2–25.8 (8.1) 327 1.0–9.6 (1) ,.001
5 and 6 9 2.3–11.0 (7.1) 75 1.0–6.4 (1) ,.001
7 5 7.1–10.0 (8.5) 172 1.0–6.8 (1) ,.001
8 and 9 0 98 1.0–7.7 (1) NAy
Note: Pathologically positive N2 lymph nodes had significantly higher median maximum standardized uptake values at each nodal station.maxSUV, Maximum
standardized uptake value; N, number of lymph nodes. *P value for Mann–Whitney test. yP value is unavailable because of an absence of pathologically
positive lymph nodes at stations 8 or 9.acic and Cardiovascular Surgery c Volume 135, Number 3 617
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TSaccuracy (87% vs 97%, P , .01), specificity (86% vs 98%,
P, .01), and positive predictive value (22% vs 64%,P, .01).
Negative predictive value remained unchanged at 99%, and
there was a trend toward decreased sensitivity, from 93%
to 81% (P5 .15, Table 3).
Furthermore, when we compared the lymph nodes that
tested true positive, false positive, and false negative by using
integrated PET/CT analysis, there were striking differences
in the corresponding maxSUVs of both the primary lesions
and the mediastinal lymph nodes (Table 4). The maxSUVs
of the primary lesions in patients with either true-positive
lymph nodes or false-positive lymph nodes were comparable
(mean, 11.8 vs 13.6; median, 10 vs 14, respectively; P 5
.145). However, the corresponding mediastinal lymph nodes
had significantly different values (mean, 11.2 vs 4.0; median,
7.6 vs 3.5, respectively; P, .01). On the other hand, patients
with false-negative lymph nodes determined by means of in-
tegrated PET/CT analysis had significantly lower maxSUVs
for both the primary lesion (mean, 5.54; median, 3.9; P ,
.01) and mediastinal lymph nodes (mean, 3.2; median, 3.3;
P , .01).
When we examined the ratios of the maxSUVs in the
lymph nodes compared with the primary tumors, we found
that patients with true-positive lymph nodes had a mean
and median ratio of 1.24 and 1.0, respectively. Patients
TABLE 3. Efficacy of integrated PET/CT by using a maxSUV
cutoff of 2.5 vs 5.3*
maxSUV cutoff
for malignancy 2.5 5.3 P valuey
Sensitivity (%) 93 81 .15
Specificity (%) 86 98 ,.001
PPV (%) 22 64 ,.001
NPV (%) 99 99 .34
Accuracy (%) 87 97 ,.001
Note: specificity, positive predictive value, and accuracy were significantly
improved when a maximum standardized uptake value cutoff of 5.3 was
used.maxSUV, Maximum standardized uptake value; PET, positron emission
tomography; CT, computed tomography; PPV, positive predictive value; NPV,
negative predictive value *The efficacy of integrated positron emission to-
mography/computed tomography was calculated by using a maximum stan-
dardized uptake value cutoff of 2.5 and then recalculated with a maximum
standardized uptake value cutoff of 5.3 for malignancy. yP value for c2 test.618 The Journal of Thoracic and Cardiovascular Surgery c Marwith false-positive lymph nodes had mean and median ratios
of 0.46 and 0.3, respectively (P , .01). Patients with false-
negative lymph nodes had mean and median ratios of 0.75
and 0.71, respectively (P 5 0.04).
Discussion
Our work confirms that the maxSUV with integrated PET/CT
scanning is a predictor of individual lymph node metastasis in
NSCLC. As suggested by previous work, lymph nodes with
a higher maxSUV have a significantly higher incidence of
metastatic disease.12 The clinical importance of this study
might be in redefining how integrated PET/CT scanning
portends to pretreatment staging of NSCLC.
That is, with integrated PET/CT, we propose that patients
with newly diagnosed NSCLC can be defined into one of 4
categories. The first are patients without mediastinal or dis-
tant uptake (maxSUV 5 background). Our work and multi-
ple other studies have shown that a negative integrated
PET/CT scan result does not need additional confirmation,
and patients can proceed directly to surgical resection.3-5,7
The second category includes patients with a high uptake
in both the primary tumor (maxSUV, .10) and the medias-
tinal lymph nodes (maxSUV, .5.3). Although this study
shows that these patients have a significantly increased risk
of malignancy in their mediastinal lymph nodes, pathologic
confirmation is still necessary to rule out infectious or inflam-
matory diseases.5,6 However, given the high likelihood of
disease, successful confirmation can be achieved by using
less-invasive procedures, such as FNA with endoscopic or
endobronchial ultrasonographic guidance.16-18 Moreover,
this would potentially preserve the ability to perform media-
stinoscopy in the posttreatment setting to determine the effec-
tiveness of neoadjuvant therapy in patients with stage IIIA
disease.19
The third category includes patients with high uptake in
the primary tumors (maxSUV, .10) and a maxSUV of less
than 5.3 in their corresponding mediastinal lymph nodes.
As shown in this study, as well as in a recent study, these
patients have a significantly lower median maxSUV ratio
between the lymph nodes and the primary tumors and are
most commonly associated with false-positive disease or
micrometastatic disease.20 Recent studies have also examined
the glucose transporter as another reason for false-negativeTABLE 4. Ratios of the maxSUV in N2 lymph nodes versus the primary tumor
Integrated PET/CT result
when using maxSUV
cutoff of 5.3 N
Median maxSUV
of N2 nodes
Median maxSUV
of primary Median ratio (range) P value*
True positive 24 7.6 10 1 (0.58–2.94)
False positive 86 3.5 14 0.3 (0.13–1.13) ,.01
False negative 7 3.3 3.9 0.71 (0.45–1.12) .04
maxSUV, Maximum standardized uptake value; PET, positron emission tomography; CT, computed tomography;N, number of lymph nodes. *P value for Mann–
Whitney test. The true-positive group was used as a reference standard.ch 2008
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propose that this population of patients, in the absence of
other factors, such as N1 disease or central tumors, might
be able to forego additional testing to rule out mediastinal
disease and instead progress directly to surgical resection,
thus avoiding delays in treatment and mitigating the added
risks of mediastinoscopy or FNA. This would present a ma-
jor deviation from the current practice of verifying all me-
diastinal lymph nodes with FDG uptake. Arguably, this
might increase the number of false-negative results ob-
tained by means of PET/CT scanning. However, a signifi-
cant number of these patients harbor micrometastatic
disease, whose benefit from neoadjuvant therapy remains
to be well documented and are currently being investi-
gated.
The final group includes patients with low uptake in both
their primary tumors (maxSUV, ,10) and their mediastinal
lymph nodes (maxSUV, ,5.3). Within our study, all of our
patients with false-negative results fell into this category.
However, these patients maintain a high maxSUV lymph
node to primary tumor ratio, thus distinguishing them from
patients with false-positive disease results who have a low
maxSUV lymph node to primary tumor ratio. Accordingly,
we find that this patient subpopulation might benefit from
mediastinoscopy to determine the extent of disease.
One of the limitations of this study was that it was retro-
spective. Thus some variables, such as timing for PET/CT im-
age acquisition and FDG injection dose, did not have a set or
predefined algorithm. Moreover, the small patient population
limited the ability to segregate and analyze our results by
using variables such as tumor size, histology, and location.
A larger prospective study would best complement this study.
In conclusion, the application of integrated PET/CT scan-
ning continues to evolve. Although it remains the most effec-
tive noninvasive staging modality, limitations that cause
false-positive (infections and inflammatory states) and
false-negative (micrometastatic disease) results still hamper
its overall effectiveness. However, this study provides evi-
dence that, in the absence of other indications for mediastino-
scopy, such as N1 disease, central tumors, or multiple tumors,
mediastinoscopy can be omitted in patients who have a max-
SUV of less than 5.3 in their N2 lymph nodes and a low max-
SUV primary tumor to mediastinal lymph node ratio, as
determined by using integrated PET/CT analysis. Future
studies will further elucidate the role of integrated PET/CT
scanning in the pretreatment staging of NSCLC.
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